DiaUnion is excited to announce its first industry partnership offering qualifying people at risk for T1D participation in the DiaPrecise precision medicine trial by Diamyd Medical.
Screening programs currently constitute a bottleneck for the identification of persons at risk for T1D and thus for the development of new therapies. The partnership with Diamyd Medical indicates that DiaUnion’s screening program is helping to alleviate this bottleneck
The partnership, hopefully, will be the first of several to bring preventive therapies to people at risk for type 1 diabetes. Read the full press release here.
